Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SHE:300255)
China · Delayed Price · Currency is CNY 55.44
+0.42 (0.76%)
Jan 28, 2026, 10:05 AM CST
SHE:300255 Revenue
Hebei Changshan Biochemical Pharmaceutical had revenue of 189.61M CNY in the quarter ending September 30, 2025, a decrease of -12.32%. This brings the company's revenue in the last twelve months to 928.01M, down -12.02% year-over-year. In the year 2024, Hebei Changshan Biochemical Pharmaceutical had annual revenue of 1.03B, down -26.92%.
Revenue (ttm)
928.01M
Revenue Growth
-12.02%
P/S Ratio
54.49
Revenue / Employee
740.04K
Employees
1,254
Market Cap
50.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.03B | -379.63M | -26.92% |
| Dec 31, 2023 | 1.41B | -925.79M | -39.63% |
| Jan 1, 2023 | 2.34B | -631.82M | -21.29% |
| Jan 1, 2022 | 2.97B | 604.26M | 25.56% |
| Dec 31, 2020 | 2.36B | 292.31M | 14.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmaron Beijing | 13.54B |
| Chongqing Zhifei Biological Products | 10.91B |
| Shanghai RAAS Blood Products | 7.95B |
| Beijing Tiantan Biological Products | 6.42B |
| Asymchem Laboratories (Tianjin) | 6.29B |
| Shanghai Allist Pharmaceuticals | 4.76B |
| Haisco Pharmaceutical Group | 4.27B |
| Hualan Biological Engineering | 4.27B |